SCHEMBL6426700

SCHEMBL6426700

COCc1cccc(BO)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 1/20 0.41
▸ FFAR1 O14842 1/20 0.39
▸ IDO1 P14902 4/20 0.38
▸ AGXT P21549 2/20 0.38
▸ CA2 P00918 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ TP53 P04637 2/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP4F2 P78329 1/20 0.34
▸ CYP4A11 Q02928 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRG2 P18507 1/20 0.34
▸ GABRB3 P28472 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34
▸ GABRB2 P47870 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL487468 0.79 IDO1 (0.48) ERN1FFAR1IDO1AGXTMAOB
SCHEMBL13418181 0.78 TP53 (0.42) IDO1TP53RAB9ASMN1; SMN2
SCHEMBL18025680 0.75 ENPP2 (0.47) SMN1; SMN2MRGPRX4
SCHEMBL3150055 0.75 ENPP2 (0.56) ERN1CA2LMNAGABRA1GABRG2
SCHEMBL29713840 0.75 ENPP2 (0.56) ERN1CA2LMNAGABRA1GABRG2
SCHEMBL2889827 0.74 CYP4F2 (0.54) ERN1FFAR1IDO1AGXTCA2
SCHEMBL25485110 0.74 IDO1 (0.47) IDO1AGXTCYP4F2CYP4A11GABRA1
SCHEMBL2567350 0.74 MRGPRX4 (0.49) ERN1FFAR1IDO1AGXTCYP4F2
SCHEMBL17934442 0.74 ENPP2 (0.54) NFKB1SMN1; SMN2
SCHEMBL2340242 0.73 TSHR (0.50) IDO1AGXTCA2TP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012055888-A1 DIAZA-SPIRO[5.5]UNDECANES USEFUL AS OREXIN RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2012-05-03 — — WO disclosed
Send feedback